FORM D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D



NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

13098	69							
OMB APPROVAL								
OMB Number:	3235-0076	Ī						
Expires:	April 30, 2008							

Estimated average burden

hours per response.....16.00

	E ONLY
Prefix	Senal
DATER	ECEIVED
1	1

Name of Offering (check if this is an Pervasis Therapeutics, Inc. Series	n amendment and name has changed, and indicate change.)	
Filing under (Check box(es) that apply):	☐ Rule 504 ☐ Rule 505 ☐ Rule 506 ☐ Section 4(6)	DULOE PROCESSED
Type of Filing: New Filing	Amendment	DEC 1 8 200s
	A. BASIC IDENTIFICATION DATA	
1. Enter the information requested about the	e issuer	THOMSON S
Name of Issuer (check if this is a Pervasis Therapeutics, Inc.	in amendment and name has changed, and indicate change.)	FINANCIAL
Address of Executive Offices One Kendall Square, Building 600, 2	(Number and Street, City, State, Zip Code) nd Floor, Cambridge, MA 02139	Telephone Number (Including Area Code) (617) 871-1202
Address of Principal Business Operations (if different from Executive Offices)	(Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code) same
Brief Description of Business The Corporation develops, manufact	ures, markets and sells biotechnology products and ser	vices.
Type of Business Organization	☐ limited partnership, already formed ☐ other (please sp☐ limited partnership, to be formed	ecify): The section of the section o
Actual or Estimated Date of Incorporal Jurisdiction of Incorporation or Organi	tion or Organization: Month Year	for State:
General Instructions		SECTION

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C.

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on the ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

SEC 1972 (6-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

12 15 0W

			TIFICATION DATA			
2. Enter the information reques	ted for the following	;:				
 Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the Each executive officer and director of corporate issuers and of corporate general managing partners of partnership issuers; and Each general and managing partnership of partnership issuers. 						
Each beneficia	owner having the p	ower to vote or dispose, or di	irect the vote or disposition	of, 10% or more o	f a clas	ss of equity securities of the issuer;
Each executive	officer and director	of corporate issuers and of c	corporate general managing	partners of partner	ship is	suers; and
Each general as	nd managing partner	ship of partnership issuers.				
Check Box(es) that Apply:	Promoter	Beneficial Owner		□ Director		General and/or Managing Partner
Full Name (Last name first, if ir	idividual)					
Nashat, Amir H.						
Business or Residence Address	(Number and Stree	et, City, State, Zip Code)				
c/o Pervasis Therapeutics, 2nd Floor	Inc., One Kendal	Square, Building 600,	Cambridge		MA	02139
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	Executive Officer	Director		General and/or Managing Partner
Full Name (Last name first, if in	idividual)			,		
Bollinger, Stephen A.						
Business or Residence Address	(Number and Stree	et, City, State, Zip Code)				
c/o Pervasis Therapeutics, 2nd Floor	Inc., One Kendal	Square, Building 600,	Cambridge		MA	02139
Check Box(es) that Apply:	Promoter	☑ Beneficial Owner	Executive Officer	Director		General and/or Managing Partner
Full Name (Last name first, if in	dividual)					•
run Name (Last name tilst, if if	(dividual)					
Edelman, Elazer R.	0.1					
Business or Residence Address	(Number and Stree	et, City, State, Zip Code)				
30 Warren Street			Brookline		MA	02445
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	Executive Officer	□ Director		General and/or Managing Partner
Full Name (Last name first, if in	đividual)					
Kania, Edwin M., Jr.						
Business or Residence Address	(Number and Stree	et, City, State, Zip Code)				
c/o Flagship Ventures, 150	CombridgeDark I	Orivo 40th Floor	Combridge			02440
Check Box(es) that Apply:	Promoter Promoter	Beneficial Owner	Cambridge Executive Officer	□ Director	MA	General and/or Managing Partner
Full Name (Last name first, if in	dividual)					
	2.710441,					
Langer, Robert S., Jr. Business or Residence Address	(Number and Stree	et, City, State, Zip Code)				
	(,,,,,				
98 Montvale Road Check Box(es) that Apply:	Promoter	Beneficial Owner	Newton Executive Officer	□ Director	MA	02458 General and/or
Check Divides and Apply.	L. Troncie	_ isenenal owner	is a second of the control	Д Бисски		Managing Partner
Full Name (Last name first, if in	dividual)		,			
Higgins, Robert F.						
Business or Residence Address	(Number and Stree	t, City, State, Zip Code)			•	
c/o Highland Capital Partne	rs, 92 Hayden Av	enue	Lexington		MA	02421
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	Director		General and/or Managing Partner
Full Name (Last name first, if in	dividual)		-			
Nugent, Helen M.						
Business or Residence Address	(Number and Stree	t, City, State, Zip Code)				
106 Grosvenor Road			Needham		MA	02492

		A. BASIC IDEN	ITIFICATION DATA			
2. Enter the information request	ted for the following:			_		
Each promoter	of the issuer, if the issu	ier has been organized wil	thin the past five years;			
Each beneficial	l owner having the pow	rer to vote or dispose, or d	irect the vote or disposition	of, 10% or more o	f a clas	s of equity securities of the issuer;
Each executive	officer and director of	corporate issuers and of	corporate general managing	partners of partner	ship is	suers; and
Each general ar	nd managing partnershi	ip of partnership issuers.				
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	☐ Executive Officer	Director		General and/or Managing Partner
Full Name (Last name first, if in	ndividual)					
Vacanti, Joseph P.						
Business or Residence Address	(Number and Street,	City, State, Zip Code)				
14 Woodside Road			Winchester		MA	01890
Check Box(es) that Apply:	Promoter	Beneficial Owner	☐ Executive Officer	Director		General and/or Managing Partner
Full Name (Last name first, if in	idividual)	-				
Polaris Venture Partners IV	, L.P.					
Business or Residence Address	(Number and Street,	City, State, Zip Code)			_	
1000 Winter Street, Suite 33	150		Waltham		MA	02451
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	Director		General and/or Managing Partner
15 H a 1	1 1					
Full Name (Last name first, if in	idividuai)					
Applied Genomic Technolo						
Business or Residence Address	(Number and Street,	City, State, Zip Code)				
150 CambridgePark Drive,	10 th Floor		Cambridge		MA	02140
Check Box(es) that Apply:	Promoter	⊠ Beneficial Owner	Executive Officer	☐ Director		General and/or
						Managing Partner
Full Name (Last name first, if in	dividual)	==				
Highland Capital Partners V						
Business or Residence Address	(Number and Street, (City, State, Zip Code)				
92 Hayden Avenue			Lexington		MA	02421
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	Executive Officer	□ Director		General and/or Managing Partner
Full Name (Last name first, if in	dividual)	_				
Collier, Earl M., Jr.						
Business or Residence Address	(Number and Street,	City, State, Zip Code)				
c/o Genzyme Corporation,	500 Kendall Street		Cambridge		MA	02142
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	Director		General and/or Managing Partner
Full Name (Last name first, if in	dividual)					
·						
Hutt, Peter Barton Business or Residence Address	(Normalism and Causas d	City State 7in Code)				
Dusiness of Residence Address	(Number and Street, V	City, state, Zip Code)				
c/o Covington & Burling, 12	201 Pennsylvania Av		Washington		DC	20004-2401
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	☐ Executive Officer	Director	Ц	General and/or Managing Partner
Full Name (Last name first, if in	dividual)					
Business or Residence Address	(Number and Street)	City, State, Zin Code)				
	tamen and outet.	engramma ap code)				
	(Use blan	k sheet, or copy and use a	dditional copies of this shee	, as necessary		

		<u>.</u>		R	INFORMA	TION ABO	OUT OFFE	RING				
1. Has th	e issuer solo	l, or does th	e issuer inte Ans	nd to sell, to	non-accre		ors in this of	fering?			Yes	No ⊠
2. What	is the minim	ium investn	nent that wil	l be accepte	d from any	individual?					. \$ N/A	
3. Does	3. Does the offering permit joint ownership of a single unit?										Yes . 🗵	No
comn If a p or sta a brol	4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchases in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only. Full Name (Last name first, if individual)											plicable
Business	or Residence	ce Address (Number and	Street, Cit	y, State, Zip	Code)			<u> </u>			
Name of	`Associated	Broker or E	Pealer									
States in	Which Pers (Check "A										☐ All S	ates
[AL]	[AK]	[AZ] [IA] [NV] [SD] [strst. if in	[AR]	[CA]	[CO] [LA] [NM] [UT]	[CT]	[DE] [MD] [NC] [VA]	[DC] [MA] [ND] [WA]	[FI]	[GA] [MN] [OK] [WI]	[HI]	[ID]
		•	····,									
Business	or Residenc	e Address (Number and	d Street, City	y, State, Zip	Code)						
Name of	Associated	Broker or D	Pealer									
States in	Which Perso (Check "A										☐ All St	ates
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO] [LA] [NM] [UT]	[CT]	[DE] MD] NC] VA]	[DC] [MA] [ND] [WA]	[FI]	[GA] [MN] [OK] [WI]	[HI] [] [MS] [] [OR] [] [WY] []	[ID] [] [MO] [] [PA] [] [PR] []
Business	or Residence	e Address (Number and	Street, City	y , State, Zi	p Code)						
Name of	Associated	Broker or D	ealer									
States in	Which Perso (Check "Al		as Solicited check indiv							• • • • • • • •	☐ All Sta	ntes
[AL] [] (IL) [] [MT] [] [RI] []	[AK] [[IZ] [[NE] [[SC] [[AZ]	[AR]	(CA) [] (KY] [] (XI] []	[CO] [] [LA] [] [NM] [] [UT] []	[CT]	[DE] [MD] [NC] [VA]	[DC] [MA] [ND] [WA]	[FI]	[GA]	[HI]	[ID]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary)

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE O	DE PROCEEDS	
1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \(\square\) and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	л ткосвых	
	Type of Security	Aggregate Offering Price	Amount Already Sold
	Debt	\$ <u>0</u>	\$ <u>0</u>
	Equity	\$ <u>5,000,001.60</u>	\$ <u>5,000,001.60</u>
	☐ Common ☑ Preferred		
	Convertible Securities (including warrants)	\$ <u>0</u>	\$ <u>0</u>
	Partnership Interests	\$ <u>0</u>	\$ <u>0</u>
	Other (Specify)	\$ <u>0</u>	\$ <u>0</u>
	Total	\$ <u>5,000,001.60</u>	\$ <u>5,000,001.60</u>
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		Aggregate Dollar Amount of Purchases
	Accredited Investors	7	\$ <u>5,000,001.60</u>
	Non-accredited Investors	<u>0</u>	\$ <u>O</u>
	Total (for filing under Rule 504 only)	N/A	\$ <u>N/A</u>
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.		Dollar Amount
	Type of offering	Security	Sold
	Rule 505	<u>N/A</u>	\$ <u>N/A</u>
	Regulation A	<u>N/A</u>	\$ <u>N/A</u>
	Rule 504	N/A	\$ <u>N/A</u>
	Total	<u>N/A</u>	\$ <u>N/A</u>
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		\$ <u>N/A</u>
	Printing and Engraving Costs		\$ <u>N/A</u>
	Legal Fees.	····	\$ <u>20,000.00</u>
	Accounting Fees		\$ <u>N/A</u>
	Engineering Fees.		\$ <u>N/A</u>
	Sales Commissions (specify finders' fees separately)		\$ <u>N/A</u>
	Other Expenses (identify)		\$ <u>N/A</u>
	Total	571	£4.000.004.00

	C. OFFERING PRIC	E, NUMBER OF INVESTORS, EXPENSES	AND US	SE O	F PR	ROCEEDS	·
		ate offering price given in response to Part C Part C Question 4.a. This difference is the "ad					\$ <u>4,980,001.60</u>
5.	each of the purposes shown. If the amount t	gross proceeds to the issuer used or proposed to for any purpose is not known, furnish an estimat otal of the payments listed must equal the adj Part C- Question 4.b. above.	e and ch	ieck	n		
					D	Payments to Officers, Directors, & Affiliates	Payments To Others
	Salaries and fees				\$ <u>0</u>		□ \$ <u>0</u>
	Purchase of real estate		· · · · · ·		\$ <u>0</u>		□ \$ <u>0</u>
	Purchase, rental or leasing and installati	ion of machinery and equipment			\$ <u>0</u>		□ \$ <u>0</u>
	Construction or leasing of plant building	gs and facilities			\$ <u>0</u>		□ \$ <u>0</u>
	Acquisition of other businesses (includi offering that may be used in exchange f	ing the value of securities involved in this for the assets or securities of another					_
	issuer pursuant to a merger)				\$ <u>0</u>		□ \$ <u>0</u>
	Repayment of indebtedness				\$ <u>0</u>		□ \$ <u>0</u>
	Working capital				\$ <u>0</u>		⋈ \$ <u>4,980,001.60</u>
	Other (specify):				\$ <u>0</u>		□ \$ <u>0</u>
					\$ <u>0</u>		□ \$0
	Column Totals				\$ <u>0</u>		 ■ \$4 ,980,001.60
	Total Payments Listed (column totals a	dded)				34,980,00 3 3 4 5 4 5 9 8 9 9 9 9 9 9 9 9 9 9	<u>1,60</u>
		D. FEDERAL SIGNATURE					
sig	nature constitutes an undertaking by the issue	ned by the undersigned duly authorized person. er to furnish to the U.S. Securities and Exchange credited investor pursuant to paragraph (b)(2) of	ge Com	missi	e is on, u	filed under Ru upon written re	ale 505, the following equest of its staff, the
Iss	uer (Print or Type)	Signature	Dat	e			
	rvasis Therapeutics, Inc.	Stay	No	vem	ber 2	28, 2006	
Na	me of Signer (Print or Type)	Title of Signer (Print or Type)					
Je	ffrey L. Quillen	Assistant Secretary					
		ATTENTION					

ATTENTION Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

See Appendix, Column 5, for state response. The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239.500) at such times as required by state law. The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform Limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform Limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied. The indersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, and understands that must be satisfied to be entitled to the Uniform Limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.						
1. Is any party described in 17 CFR 230. of such rule?	262 presently subject to any disqualification prov					
	See Appendix, Column 5, for state res	sponse.				
-	•	state in which this notice is filed, a notice on Form D				
-	takes to furnish to the state administrators, upon	written request, information furnished by the issuer to				
Offering Exemption (ULOE) of the	state in which this notice is filed and understa					
The issuer has read this notification an undersigned duly authorized person.	d knows the contents to be true and has duly of	caused this notice to be signed on its behalf by the				
Issuer (Print or Type)	Signature	Date				
Pervasis Therapeutics, Inc.	Joy Car	November 28, 2006				
Name (Print or Type)	Title (Print or Type)					
leffrey L. Quillen	Assistant Socretary					

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

APPENDIX

1	Intend to non-ac investors (Part B	ccredited in State	Type of security and aggregate offering price offered in state (Part C-Item 1)		Type of investor and amount purchased in State (Part C-Item 2)					
State	Yes	No		Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No	
AL										
AK										
ΑZ										
AR								ļ		
CA								-		
со										
СТ								<u> </u>		
DE										
DC								ļ		
FL								ļ		
GA										
н		-				-		ļ .— —		
ID								-		
IL								ļ		
IN								-		
IA										
KS		-								
KY										
LA		 		<u> </u>				<u> </u>		
ME										
MD			Series B Convertible							
MA		×	Preferred: Aggregate \$5,000,001.60	7	\$5,000,001.60	0	0		х	
МІ				-						
MN					-			ļ		
MS				<u> </u>						

APPENDIX 2 4 1 Disqualification Type of security under State ULOE Intend to sell and aggregate Type of investor and amount purchased in State (Part C-Item 2) (if yes, attach to non-accredited offering price explanation of investors in State offered in state waiver granted) (Part E-Item 1) (Part B-Item1) (Part C-Item 1) Number of Number of Accredited Non-Accredited **Investors** Amount Investors Amount Yes No State Yes No МО MTNE NVNH NJ NM NYNC ND OHOK OR PA RI SCSD TN TXUT VTVAWA WV

WI

				A	APPENDIX					
1	4	2	3		Disqual under Sta	ification				
Intend to sell to non-accredited investors in State (Part B-Item1) Type of security and aggregate offering price offered in state (Part C-Item 1)			and aggregate offering price offered in state	Type of investor and amount purchased in State (Part C-Item 2)					(if yes, attach explanation of waiver granted) (Part E-Item 1)	
State	Yes	No		Number of Accredited Investors	Amount	Number of Non- Accredited Investors	Amount	Yes	No	
WY										
PR_										